ERBB2 and triple-negative breast carcinoma: Conversely, a 2022 pilot study investigating PD1 polymorphism in breast cancer patients found no association with PD1 (rs36084323) and particular breast cancer subtypes that included luminal A, luminal B, HER2 positive, and triple negative breast cancer [28].